| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/19/2013 | CN103156867A Medical composition for preventing or treating amyloid beta peptide related diseases or conditions |
| 06/19/2013 | CN103156860A Olanzapine composition and preparation method thereof |
| 06/19/2013 | CN103156855A Paracetamol and caffeine slow-release capsule and preparation method thereof |
| 06/19/2013 | CN103156839A Method of applying procyanidins from lotus seed pots to prevent brain oxidative stress injury caused by extremely low-frequency electromagnetic fields (ELF-EMF) |
| 06/19/2013 | CN103156817A Rizatriptan drug absorbed through mouth mucosa |
| 06/19/2013 | CN103156816A Almotriptan drug absorbed through mouth mucosa |
| 06/19/2013 | CN103156810A Propofol microemulsion composition |
| 06/19/2013 | CN103156808A Gastrodin injection liquid and preparation method thereof |
| 06/19/2013 | CN103156807A Buflomedilhydroc hloride injection and preparation method thereof |
| 06/19/2013 | CN103156460A Sleeping-assistance drug pillow |
| 06/19/2013 | CN102617723B Scorpion venom active peptides, preparation method thereof and application |
| 06/19/2013 | CN102580100B Preparation method and application of enzyme regulated nanometer supermolecule vesicle |
| 06/19/2013 | CN102526474B Chinese medicine composition for treating neurasthenia |
| 06/19/2013 | CN102499953B Process for extracting total phenyl propanoid from paulownia bark of paulownia tomentosa (original variety) by adopting supercritical CO2 fluid technology |
| 06/19/2013 | CN102406831B Chinese medicine composition for treating insomnia and dreamful sleep and preparation method of Chinese medicine composition |
| 06/19/2013 | CN102302751B Chinese medicine for treating migraine |
| 06/19/2013 | CN102302683B Traditional Chinese medicine compound preparation used for treating headache, and preparation method thereof |
| 06/19/2013 | CN102240307B Preparation method of ginkgo leaf extract |
| 06/19/2013 | CN102228454B Brain targeting via olfactory pathway fragrant essential oil compound and monomer pharmaceutical composition with functions for preventing and treating brain atrophy and activating brain cells |
| 06/19/2013 | CN102199587B Functional mutant of human plasminogen, its preparation method and application |
| 06/19/2013 | CN102178956B Preparation, medical application and composition of 20S-protopanaxadiol beta-cyclodextrin inclusion compound |
| 06/19/2013 | CN102178664B Application of schizandrol A, schizandrin and schizandrol extract to prevention and treatment of senile dementia |
| 06/19/2013 | CN102167695B Benzimidazole-carbonyl-pyridine-amino-ehtyl-propionate hemihyrate and its use |
| 06/19/2013 | CN102133406B Oil-phase preparation for opiates medicaments and preparation method thereof |
| 06/19/2013 | CN102065894B Antibody bound synthetic vesicle containing active agent molecules |
| 06/19/2013 | CN102046171B Transdermal preparation |
| 06/19/2013 | CN101914168B Medical applications and preparation methods of Pleurotus ferulae Lanzi polysaccharide and composites thereof |
| 06/19/2013 | CN101904871B Three-ant health wine and preparation method thereof |
| 06/19/2013 | CN101899116B Non-invasive high-penetrability epidermal growth factor and application thereof |
| 06/19/2013 | CN101880276B Substituted diazepan compounds as orexin receptor antagonists |
| 06/19/2013 | CN101605764B Fast dissociating dopamine 2 receptor antagonists |
| 06/19/2013 | CN101594871B Pyrrolopyrimidine compounds and their uses |
| 06/19/2013 | CN101578271B 4-imidazolines as taar's ligands |
| 06/19/2013 | CN101486701B Analogue compound, and analogue and medical use thereof |
| 06/19/2013 | CN101486700B 8-acetyl chromanone compound, and analogue and medical use thereof |
| 06/19/2013 | CN101407456B Effective ingredient having beta-secretase inhibition effect in Homalonema occulta |
| 06/19/2013 | CN101293016B Application of cistanche salsa extract in preparing medicament for treating parkinsonism |
| 06/19/2013 | CN101260063B Gamma-aminobutyric acid derivative and its preparing process |
| 06/18/2013 | US8466172 Stabilization of hypoxia inducible factor (HIF) alpha |
| 06/18/2013 | US8466153 Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists |
| 06/18/2013 | US8466144 Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
| 06/18/2013 | US8466105 Treatment of stroke using domain V of perlecan |
| 06/18/2013 | US8465774 Sequestered antagonist formulations |
| 06/18/2013 | US8465727 Biomarkers for the diagnosis of ALS |
| 06/18/2013 | US8464711 Methods for treating headaches |
| 06/18/2013 | CA2812178A1 Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
| 06/18/2013 | CA2566212C Heteroaryl-substituted cyclohexyl-1,4-diamine derivatives |
| 06/18/2013 | CA2522669C Postnatal stem cells and uses thereof |
| 06/18/2013 | CA2483656C Reduced formate poly(alkylene oxide) for a controlled release dosage form of reboxetine |
| 06/18/2013 | CA2481512C Peptide inhibitors of protein kinase c.gamma. for pain management |
| 06/18/2013 | CA2429097C Composition of solutions for organ protection |
| 06/18/2013 | CA2418144C Urocortin proteins and uses thereof |
| 06/13/2013 | WO2013086425A1 The hydrobromide salt of pridopidine |
| 06/13/2013 | WO2013086330A1 Nutritional compositions comprising curcumin and docosahexaenoic acid for improving cognition |
| 06/13/2013 | WO2013086207A1 Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
| 06/13/2013 | WO2013086200A1 Composition and method for neuropeptide s receptor (npsr) antagonists |
| 06/13/2013 | WO2013085781A1 Spirothienopyran- piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse |
| 06/13/2013 | WO2013085018A1 Phenylpyrrole derivative |
| 06/13/2013 | WO2013085017A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | WO2013085016A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | WO2013084532A1 Prophylactic or therapeutic agent for dysuria |
| 06/13/2013 | WO2013084238A1 Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide |
| 06/13/2013 | WO2013084236A1 Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als) |
| 06/13/2013 | WO2013084182A1 Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent |
| 06/13/2013 | WO2013084060A1 Quaternized buprenorphine analogs |
| 06/13/2013 | WO2013083994A1 Hydantoin derivatives useful as kv3 inhibitors |
| 06/13/2013 | WO2013083887A1 Novel association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an nmda receptor antagonist and the pharmaceutical compositions which contain said association |
| 06/13/2013 | WO2013083741A1 1,2,4 -triazoles as allosteric modulators of mglu5 receptor activity for the treatment of schizophrenia of dementia |
| 06/13/2013 | WO2013083685A1 Process for recovery of nalmefene hydrochloride |
| 06/13/2013 | WO2013083591A1 Substituted pyrazoles as mglu5 receptor modulators |
| 06/13/2013 | WO2013083574A1 Composition for treating parkinson's disease. |
| 06/13/2013 | WO2013083557A1 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives |
| 06/13/2013 | WO2013083556A1 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives |
| 06/13/2013 | WO2013083070A1 1, 4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof |
| 06/13/2013 | WO2013043232A3 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer |
| 06/13/2013 | WO2013025042A3 Composition including stem cell-derived microvesicles for promoting neurogenesis |
| 06/13/2013 | US20130150311 Mixed poloxamer excipients |
| 06/13/2013 | US20130150287 RECOMBINANT PROTEIN FOR INTRACELLULAR DELIVERY OF siRNA AND COMPOSITION COMPRISING THE SAME |
| 06/13/2013 | CA2858752A1 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists |
| 06/13/2013 | CA2858576A1 Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
| 06/13/2013 | CA2858571A1 Composition and method for neuropeptide s receptor (npsr) antagonists |
| 06/13/2013 | CA2858342A1 Phenylpyrrole derivative |
| 06/13/2013 | CA2858192A1 Medical food for the dietary management of depression and anxiety and methods thereof |
| 06/13/2013 | CA2858164A1 Pyridone derivative and medicine containing same |
| 06/13/2013 | CA2857096A1 Process for recovery of nalmefene hydrochloride |
| 06/13/2013 | CA2856654A1 Hydantoin derivatives useful as kv3 inhibitors |
| 06/13/2013 | CA2855994A1 Phosphate esters of noribogaine |
| 06/13/2013 | CA2855990A1 Sulfate esters of noribogaine |
| 06/13/2013 | CA2853891A1 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives |
| 06/13/2013 | CA2853500A1 Spirothienopyran- piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse |
| 06/13/2013 | CA2852366A1 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives |
| 06/12/2013 | EP2602255A1 Fused heterocyclic ring compound |
| 06/12/2013 | EP2602254A1 Heterocyclic compound |
| 06/12/2013 | EP2601966A1 Treatment of neurological or neurodegenerative disorders |
| 06/12/2013 | EP2601954A1 Therapeutic agent for disease |
| 06/12/2013 | EP2601949A2 Pharmaceutical compositions |
| 06/12/2013 | EP2601948A1 Preparation for treatment of spinal cord injury |
| 06/12/2013 | EP2601942A1 Novel combination of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing same |
| 06/12/2013 | EP2601294A1 Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins |
| 06/12/2013 | EP2601192A1 Fused heterocyclic compounds |